## 2017 HALF-YEAR RESULTS

28 July 2017

Mr. Christian Mulliez
Chief Financial Officer

L'ORÉAL

## Consolidated group sales at the end of June 2017



| Growth at constant exchange rates | $+4.3 \%$ |
| :--- | :---: |
| - external growth impact | $+1.0 \%$ |
| - TBS disposal impact | $-3.1 \%$ |
| Exchange rate impact | $\mathbf{+ 1 . 8 \%}$ |
| Reported growth | $+4.0 \%$ |

2016
2017

## Changes in exchange rates

 (against the euro)|  | Weight in <br> consolidated sales at <br> 30 June 2017 | Average rate <br> January - June <br> $\mathbf{2 0 1 6}$ | Average rate <br> January - June <br> $\mathbf{2 0 1 7}$ | Change <br> H1-2017 vs. H1-2016 |
| :--- | :---: | :---: | :---: | :---: |
| Euro | $24.5 \%$ | - | - | - |
| US Dollar (1 $€=$ ) | $26.3 \%$ | 1.115 | 1.082 | $+3.1 \%$ |
| Chinese Yuan | $8.2 \%$ | 0.137 | 0.134 | $-1.9 \%$ |
| Sterling Pound | $5.6 \%$ | 1.285 | 1.163 | $-9.5 \%$ |
| Brazilian Real | $2.8 \%$ | 0.242 | 0.291 | $+20.0 \%$ |
| Russian Ruble | $2.7 \%$ | 0.013 | 0.016 | $+24.5 \%$ |
| Canadian Dollar | $2.7 \%$ | 0.674 | 0.693 | $+2.9 \%$ |
| Japanese Yen (1000) | $1.7 \%$ | 8.039 | 8.224 | $+2.3 \%$ |
| Australian Dollar | $1.6 \%$ | 0.657 | 0.697 | $+6.1 \%$ |
| Mexican Peso | $1.5 \%$ | 0.050 | 0.048 | $-4.0 \%$ |

## Consolidated sales by division at the end of June 2017

|  | H1-2016 <br> Reported <br> (€ million) | H1-2017 <br> (€ million) | Like-for-like | At constant exchange rates | Reported |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Professional Products | 1724 | 1739 | -0.7\% | -1.1\% | +0.9\% |
| Consumer Products | 6155 | 6389 | +1.9\% | +1.8\% | +3.8\% |
| L'Oréal Luxe | 3595 | 4149 | +10.5\% | +13.5\% | +15.4\% |
| Active Cosmetics | 1021 | 1135 | +4.6\% | +9.0\% | +11.1\% |
| Divisions Total | 12496 | 13412 | +4.3\% | +5.3\% | +7.3\% |
| The Body Shop | 399 |  |  |  |  |
| Consolidated Total | 12895 | 13412 | +4.3\% |  | +4.0\% |

## Total divisions sales by region at the end of June 2017*

|  |  |  | $\%$ change |  |
| :--- | :---: | :---: | :---: | :---: |
|  | In $€$ million | Like-for-like | Reported |  |
| Western Europe | 4202.7 | $+3.0 \%$ | $+1.6 \%$ |  |
| North America | 3824.8 | $+3.1 \%$ | $+10.5 \%$ |  |
| New Markets | 5384.4 | $+6.2 \%$ | $+9.9 \%$ |  |
| of which: |  |  |  |  |
| - Asia, Pacific | 3135.4 | $+8.1 \%$ | $+9.4 \%$ |  |
| $\quad$ - Latin America | 985.1 | $+5.9 \%$ | $+14.1 \%$ |  |
| - Eastern Europe | 908.5 | $+9.4 \%$ | $+17.4 \%$ |  |
| $\quad$ - Africa, Middle-East | 355.4 | $-13.2 \%$ | $-10.9 \%$ |  |
| Divisions Total | 13411.9 | $+4.3 \%$ | $+7.3 \%$ |  |

## Consolidated profit and loss account:

 from sales to operating profit(in million euros)
Sales
Cost of sales
Gross profit
Research and development expenses
Advertising and promotion expenses
Selling, general and administrative expenses

## Operating profit

| H1-2016 | As a \% of sales | 2016 | As a \% of sales | H1-2017 | As a \% of sales | $\begin{gathered} \text { Change } \\ \text { H1-2017 vs. } \\ \text { H1-2016 } \end{gathered}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 12894.6 | 100.0\% | 25837.1 | 100.0\% | 13411.9 | 100.0\% | +4.0\% |  |
| -3561.2 | 27.6\% | -7341.7 | 28.4\% | -3780.5 | 28.2\% |  |  |
| 9333.4 | 72.4\% | 18495.4 | 71.6\% | 9631.4 | 71.8\% | +3.2\% |  |
| -414.2 | 3.2\% | -849.8 | 3.3\% | -425.1 | 3.2\% |  |  |
| -3 790.9 | 29.4\% | -7498.7 | 29.0\% | -3913.5 | 29.2\% |  |  |
| -2 764.7 | 21.4\% | -5607.0 | 21.7\% | -2 762.4 | 20.6\% |  |  |
| 2363.6 | 18.3\% | 4539.9 | 17.6\% | 2530.4 | 18.9\% | +7.1\% | +60bp |

## Operating profit margin by division

| (as a \% of sales) | H1-2016 <br> reported | 2016 <br> reported | H1-2017 |
| :--- | :---: | :---: | :---: |
| Professional Products | $19.6 \%$ | $20.3 \%$ | $18.4 \%$ |
| Consumer Products | $21.2 \%$ | $20.2 \%$ | $19.8 \%$ |
| L'Oréal Luxe | $21.3 \%$ | $21.2 \%$ | $23.4 \%$ |
| Active Cosmetics | $27.7 \%$ | $23.2 \%$ | $26.7 \%$ |
| Total divisions | $21.6 \%$ | $20.7 \%$ | $\mathbf{2 1 . 3 \%}$ |
| before non-allocated expenses | $-2.5 \%$ | $-2.6 \%$ | $-2.5 \%$ |
| Non-allocated expenses* | $19.1 \%$ | $18.1 \%$ | $18.9 \%$ |
| Total divisions | $-5.6 \%$ | $3.7 \%$ | - |
| after non-allocated expenses | $18.3 \%$ | $17.6 \%$ | $\mathbf{1 8 . 9} \%$ |
| The Body Shop |  |  |  |
| Group |  |  |  |

* Central group expenses, fundamental research expenses, stock-option \& free grant of shares expenses and miscellaneous items as a \% of total divisions sales


## Consolidated profit and loss account: from operating profit to net profit excluding non-recurring items

## (in million euros)

## Operating profit

Financial revenues-expenses before dividends received
Sanofi dividends
Profit before tax and associates, excluding non-recurring items
Income tax excluding non-recurring items
Share of profit in associates,
excluding non-recurring items
Non-controlling interests
Net profit excluding non-recurring items, attributable to owners of the company

| H1-2016 <br> Reported | 2016 <br> Reported | H1-2017 | Change <br> H1-17 vs. H1-16 |
| ---: | ---: | ---: | :---: |
| $\mathbf{2 3 6 3 . 6}$ | $\mathbf{4 5 3 9 . 9}$ | $\mathbf{2 5 3 0 . 4}$ | $\mathbf{+ 7 . 1 \%}$ |
| +1.8 | -19.3 | -9.9 |  |
| 346.5 | 346.5 | 350.0 |  |
| $\mathbf{2 7 1 1 . 9}$ | $\mathbf{4 8 6 7 . 1}$ | $\mathbf{2 8 7 0 . 5}$ | $\mathbf{+ 5 . 8 \%}$ |
| -684.1 | -1216.8 | -687.5 |  |
| -0.1 | -0.1 | - |  |
| -2.4 | -3.0 | +2.8 |  |
| 2025.4 | 3647.2 | $2185.8^{(1)}$ | $+7.9 \%$ |
| 3.59 (2) $^{(2)}$ | $6.46{ }^{(2)}$ | $3.88{ }^{(3)}$ | $+8.1 \%$ |

(1): Net profit from continuing operations, excluding non-recurring items, attributable to owners of the company
(2): Diluted earnings per share, excluding non-recurring items, attributable to owners of the company, reported in H1-2016 and 2016
(3): Diluted earnings per share based on net profit from continuing operations, excluding non-recurring items, attributable to owners of the company

## Consolidated profit and loss account: from net profit excluding non-recurring items to net profit

(in million euros)
Net profit excluding non-recurring items, attributable to owners of the company
Non-recurring items

- of which:
- other income and expenses -522.3
- taxes on non-recurring items

Impact on net profit attributable to owners of the company
of applying IFRS 5 regarding discontinued operations
Net profit attributable to owners of the company

| H1-2016 <br> reported | 2016 <br> reported | H1-2017 | Change H1-17 <br> vs. H1-16 |
| ---: | ---: | :---: | :---: |
| $\mathbf{2 0 2 5 . 4}$ | $\mathbf{3 6 4 7 . 2}$ | $\mathbf{2 1 8 5 . 8}{ }^{(1)}$ | $+7.9 \%$ |
| -545.9 | -541.5 | -119.1 |  |
| -522.3 | -543.7 | -96.2 |  |
| -23.6 | +2.2 | -22.8 |  |
|  |  | -29.1 |  |
| $\mathbf{1 4 7 9 . 5}$ | $\mathbf{3 1 0 5 . 8}$ | $\mathbf{2 0 3 7 . 5}$ | $+37.7 \%$ |

## Cash flow statements

| Change |  |  |  |
| :--- | ---: | ---: | ---: | :---: |
| (in million euros) | H1-2016 <br> Reported | 2016 <br> Reported | H1-2017 |
| H1-17 vs. H1-16 |  |  |  |

(1): including the impact on net profit of applying IFRS 5 to discontinued operations.
(2): Others include disposal of treasury stock and purchase of non-controlling interests

## Assets

31 Dec. 201630 June 2017
Reported

- Current assets
- Cash \& cash equivalents
- Assets for disposal
Total Assets

35.6


Liabilities
31 Dec. 2016
Reported


Total Liabilities 35.6

30 June 2017


## Net cash/net debt and gearing

| in million euros | 30 June 2016 <br> Reported | 30 June 2017 |  | in million euros | 31 Dec. 2016 <br> Reported |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Net debt | 344 | 1492 |  | Net cash | 481 |
| Gearing* | $1.6 \%$ | $6.1 \%$ |  | Gearing |  |

## Appendix

## Appendix: Compared consolidated income statements From sales to operating profit

(in million euros)

| H1-2016 | As a \% of sales | 2016 | As a \% of sales | H1-2017 | As a \% of sales |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 12496.0 | 100.0 \% | 24916.3 | 100.0 \% | 13411.9 | 100.0 \% |
| -3 447.7 | 27.6 \% | -7 068.6 | 28.4 \% | -3780.5 | 28.2 \% |
| 9048.3 | 72.4 \% | 17847.7 | 71.6 \% | 9631.4 | 71.8 \% |
| -409.7 | 3.3 \% | -841.2 | 3.4 \% | -425.1 | 3.2 \% |
| -3677.8 | 29.4 \% | -7 264.4 | 29.2 \% | -3913.5 | 29.2 \% |
| -2 575.1 | 20.6 \% | -5 236.0 | 21.0 \% | -2 762.4 | 20.6 \% |
| 2385.7 | 19.1 \% | 4506.1 | 18.1 \% | 2530.4 | 18.9 \% |

## Appendix: Compared consolidated income statements from operating profit to net profit excluding non-recurring items

(in million euros)

Operating profit
Financial revenues-expenses before dividends received
Sanofi dividends
Profit before tax and associates, excluding non- recurring items
Income tax excluding non-recurring items
Share of profit in associates, excluding non-recurring items
Non-controlling interests
Net profit from continuing operations, excluding non-recurring items, attributable to owners of the company

| Earnings per share ${ }^{(1)}$ (in euros) | 3.63 | 6.41 | 3.88 |
| :--- | :--- | :--- | :--- | :--- |
| Diluted average number of shares | 564258226 | 564509135 | 563423701 |

## Appendix: Compared Cash flow statements

| (in million euros) | H1-2016 | 2016 | H1-2017 | Change H1-17 vs. H1-16 |
| :---: | :---: | :---: | :---: | :---: |
| Net profit | 1481.8 | 3108.7 | 2034.7 | +37.3\% |
| Depreciation, amortisation and provisions | 869.1 | 1382.3 | 556.9 |  |
| Capital gains and losses on disposals of assets, changes in deferred taxes and others ${ }^{(1)}$ | +120.3 | +165.4 | +42.5 |  |
| Share of profit in associates, net of dividends received | - | +0.1 | +0.2 |  |
| Cash flow | 2471.2 | 4656.5 | 2634.3 | +6.6\% |
| Changes in working capital | -510.9 | +4.3 | -362.8 |  |
| Investments | -574.5 | -1334.9 | -641.9 |  |
| Operating net cash | 1385.8 | 3325.9 | 1629.6 | +17.6\% |
| Dividends paid | -1796.5 | -1832.9 | -1899.7 |  |
| Acquisitions | -20.7 | -1209.0 | -1240.0 |  |
| Acquisitions of treasury stock | -499.1 | -499.1 | -499.4 |  |
| Capital increase | +89.4 | +163.2 | +72.3 |  |
| Others ${ }^{(2)}$ | -15.2 | -8.8 | -17.4 |  |
| Residual cash flow after acquisitions | -856.3 | -60.7 | -1954.6 |  |

[^0]

## -Avertissement / Disclaimer

"Ce document ne constitue pas une offre de vente ou la sollicitation d' une offre d' achat de titres L' Oréal. Si vous souhaitez obtenir des informations plus complètes concernant L' Oréal nous vous invitons à vous reporter aux documents publics déposés en France auprès de l' Autorité des Marchés Financiers (également disponibles en version anglaise sur notre site Internet www.loreal-finance.com).Ce document peut contenir certaines déclarations de nature prévisionnelle. Bien que la Société estime que ces déclarations reposent sur des hypothèses raisonnables à la date de publication du présent communiqué, elles sont par nature soumises à des risques et incertitudes pouvant donner lieu à un écart entre les chiffres réels et ceux indiqués ou induits dans ces déclarations.»
"This document does not constitute an offer to sell, or a solicitation of an offer to buy, L'Oréal shares. If you wish to obtain more comprehensive information about L'Oréal, please refer to the public documents registered in France with the Autorité des Marchés Financiers (which are also available in English on our Internet site: www.loreal-finance.com). This document may contain some forward-looking statements. Although the Company considers that these statements are based on reasonable hypotheses at the date of publication of this release, they are by their nature subject to risks and uncertainties which could cause actual results to differ materially from those indicated or projected in these statements."


[^0]:    The announcement on 27 June 2017 of the signing of the contract for the sale of The Body Shop leads to applying IFRS 5 accounting rule to discontinued operations at 30 June 2017.
    (1): including the impact on net profit of applying IFRS 5 to discontinued operations.
    (2): Others include disposal of treasury stock and purchase of non-controlling interests.

